The ANX price crash in summer of 2011 was an FDA new drug application that FDA denied because some idiot overseas failed to follow proper drug label chain of custody protocall, or something like that.
The prior crash was a failed to get FDA approval approval for a new drug trial because the shelf life tests were no longer valid because they changed suppliers. IDIOTs running the company. But that also made it cheap. I think it is still selling for less than cash in the bank (or it was).
Market Data 
Markets 
AI
